- JP-listed companies
- Cash flow
(4888) Cash flow
Market cap
¥24.3B
P/E ratio
-26.6x
Develops BNCT cancer treatment that uses boron and neutrons to selectively destroy cancer cells while minimizing damage to healthy tissue.
| 2019/03 | 2020/03 | 2021/03 | 2022/03 | 2023/03 | 2024/03 | 2025/03 | |
| Depreciation & amortization | 24 | 29 | 31 | 34 | 35 | 35 | 35 |
| Cash from operations | -771 | -914 | -773 | -1,081 | -828 | -877 | 140 |
| Capital expenditures | -11 | -25 | -21 | -46 | -25 | -11 | -4 |
| Cash from investing | -15 | 1,558 | -23 | -351 | -30 | -9 | 288 |
| Repurchases of common stock | - | - | - | - | -0 | - | -0 |
| Proceeds from issuance of term debt, net | - | 1,600 | - | - | - | - | 731 |
| Repayments of term debt | - | -1,628 | -160 | -160 | -160 | -160 | -947 |
| Cash from financing | - | -69 | -332 | 3,829 | 292 | 228 | 721 |
| Free cash flow | |||||||
| FCF margin (%) | - | - |